vs
牛津地产（IIPR）与RHYTHM PHARMACEUTICALS, INC.（RYTM）财务数据对比。点击上方公司名可切换其他公司
牛津地产的季度营收约是RHYTHM PHARMACEUTICALS, INC.的1.2倍（$66.7M vs $57.3M），牛津地产净利率更高（47.8% vs -83.0%，领先130.7%），RHYTHM PHARMACEUTICALS, INC.同比增速更快（36.9% vs -13.1%），过去两年RHYTHM PHARMACEUTICALS, INC.的营收复合增速更高（48.5% vs -6.0%）
牛津地产是一家加拿大跨国企业，业务涵盖房地产投资、开发与物业管理。其投资组合包含写字楼、零售、工业、多户住宅、生命科学及酒店类资产。该公司1960年以私营企业形式创立，自2003年起成为安大略省市政雇员退休系统（OMERS）的全资子公司，总部设于多伦多，在纽约、伦敦、澳大利亚、新加坡及卢森堡均设有区域总部。
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业，主要开发和商业化针对罕见遗传性肥胖症的靶向疗法，覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症，服务北美、欧洲地区缺少有效治疗方案的患者群体。
IIPR vs RYTM — 直观对比
营收规模更大
IIPR
是对方的1.2倍
$57.3M
营收增速更快
RYTM
高出50.0%
-13.1%
净利率更高
IIPR
高出130.7%
-83.0%
两年增速更快
RYTM
近两年复合增速
-6.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.7M | $57.3M |
| 净利润 | $31.8M | $-47.5M |
| 毛利率 | — | 91.6% |
| 营业利润率 | 47.8% | -82.2% |
| 净利率 | 47.8% | -83.0% |
| 营收同比 | -13.1% | 36.9% |
| 净利润同比 | -20.4% | -9.6% |
| 每股收益（稀释后） | $1.07 | $-0.73 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IIPRRYTM
| Q4 25 | $66.7M | $57.3M | ||
| Q3 25 | $64.7M | $51.3M | ||
| Q2 25 | $62.9M | $48.5M | ||
| Q1 25 | $71.7M | $32.7M | ||
| Q4 24 | $76.7M | $41.8M | ||
| Q3 24 | $76.5M | $33.3M | ||
| Q2 24 | $79.8M | $29.1M | ||
| Q1 24 | $75.5M | $26.0M |
净利润IIPRRYTM
| Q4 25 | $31.8M | $-47.5M | ||
| Q3 25 | $29.3M | $-52.9M | ||
| Q2 25 | $26.0M | $-46.6M | ||
| Q1 25 | $31.1M | $-49.5M | ||
| Q4 24 | $40.0M | $-43.3M | ||
| Q3 24 | $40.2M | $-43.6M | ||
| Q2 24 | $42.0M | $-32.3M | ||
| Q1 24 | $39.4M | $-141.4M |
毛利率IIPRRYTM
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
营业利润率IIPRRYTM
| Q4 25 | 47.8% | -82.2% | ||
| Q3 25 | 45.5% | -102.6% | ||
| Q2 25 | 45.9% | -93.4% | ||
| Q1 25 | 47.4% | -143.7% | ||
| Q4 24 | 54.7% | -98.6% | ||
| Q3 24 | 54.8% | -132.0% | ||
| Q2 24 | 53.1% | -139.2% | ||
| Q1 24 | 55.7% | -538.7% |
净利率IIPRRYTM
| Q4 25 | 47.8% | -83.0% | ||
| Q3 25 | 45.3% | -103.1% | ||
| Q2 25 | 41.4% | -96.1% | ||
| Q1 25 | 43.3% | -151.4% | ||
| Q4 24 | 52.2% | -103.6% | ||
| Q3 24 | 52.6% | -131.2% | ||
| Q2 24 | 52.6% | -110.9% | ||
| Q1 24 | 52.3% | -544.4% |
每股收益（稀释后）IIPRRYTM
| Q4 25 | $1.07 | $-0.73 | ||
| Q3 25 | $0.97 | $-0.82 | ||
| Q2 25 | $0.86 | $-0.75 | ||
| Q1 25 | $1.03 | $-0.81 | ||
| Q4 24 | $1.35 | $-0.71 | ||
| Q3 24 | $1.37 | $-0.73 | ||
| Q2 24 | $1.44 | $-0.55 | ||
| Q1 24 | $1.36 | $-2.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $47.6M | $388.9M |
| 总债务越低越好 | $393.7M | — |
| 股东权益账面价值 | $1.8B | $139.1M |
| 总资产 | $2.4B | $480.2M |
| 负债/权益比越低杠杆越低 | 0.21× | — |
8季度趋势，按日历期对齐
现金及短期投资IIPRRYTM
| Q4 25 | $47.6M | $388.9M | ||
| Q3 25 | $41.9M | $416.1M | ||
| Q2 25 | $104.9M | $291.0M | ||
| Q1 25 | $133.3M | $314.5M | ||
| Q4 24 | $151.2M | $320.6M | ||
| Q3 24 | $172.4M | $298.4M | ||
| Q2 24 | $160.9M | $319.1M | ||
| Q1 24 | $173.5M | $201.2M |
总债务IIPRRYTM
| Q4 25 | $393.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益IIPRRYTM
| Q4 25 | $1.8B | $139.1M | ||
| Q3 25 | $1.9B | $148.8M | ||
| Q2 25 | $1.9B | $-11.9M | ||
| Q1 25 | $1.9B | $18.9M | ||
| Q4 24 | $1.9B | $21.7M | ||
| Q3 24 | $1.9B | $11.2M | ||
| Q2 24 | $1.9B | $39.3M | ||
| Q1 24 | $2.0B | $61.6M |
总资产IIPRRYTM
| Q4 25 | $2.4B | $480.2M | ||
| Q3 25 | $2.3B | $506.9M | ||
| Q2 25 | $2.3B | $372.7M | ||
| Q1 25 | $2.4B | $386.7M | ||
| Q4 24 | $2.4B | $392.3M | ||
| Q3 24 | $2.4B | $363.6M | ||
| Q2 24 | $2.4B | $381.8M | ||
| Q1 24 | $2.4B | $258.7M |
负债/权益比IIPRRYTM
| Q4 25 | 0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $198.2M | $-25.4M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 6.22× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流IIPRRYTM
| Q4 25 | $198.2M | $-25.4M | ||
| Q3 25 | $45.6M | $-26.6M | ||
| Q2 25 | $48.4M | $-23.3M | ||
| Q1 25 | $54.2M | $-40.4M | ||
| Q4 24 | $258.4M | $-18.8M | ||
| Q3 24 | $64.9M | $-25.2M | ||
| Q2 24 | $64.2M | $-29.1M | ||
| Q1 24 | $71.6M | $-40.7M |
现金转化率IIPRRYTM
| Q4 25 | 6.22× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.86× | — | ||
| Q1 25 | 1.75× | — | ||
| Q4 24 | 6.46× | — | ||
| Q3 24 | 1.61× | — | ||
| Q2 24 | 1.53× | — | ||
| Q1 24 | 1.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
